Palmitoyl Tetrapeptide-7 Peptide

Palmitoyl Tetrapeptide-7 reduces IL-6 secretion from endothelial cells by up to 21%. IL-6 is a key pro-inflammatory cytokine involved in skin aging, glycation, and collagen degradation. By reducing chronic low-grade inflammation (inflammaging), it helps preserve dermal matrix integrity.

Palmitoyl Tetrapeptide-7 is a lipidated signal peptide consisting of the tetrapeptide sequence Gly-Gln-Pro-Arg (GQPR) conjugated to palmitic acid (C16 fatty acid) at the N-terminus. The palmitoyl moiety dramatically increases lipophilicity, enabling the peptide to cross the stratum corneum lipid bilayer and reach deeper layers of the epidermis and upper dermis where signalling effects on fibroblasts and keratinocytes occur. The GQPR sequence is derived from the immunoglobulin G (IgG) heavy chain hinge region and was originally identified as a fragment with immunomodulatory activity.

Suppression of NF-κB Signalling

The central mechanism investigated for Palmitoyl Tetrapeptide-7 involves attenuation of the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway. Chronic low-grade inflammation in dermal tissue—often termed inflammaging—is driven by persistent NF-κB activation in response to ultraviolet exposure, advanced glycation end-products (AGEs), and oxidative stress. In vitro studies on cultured human fibroblasts and keratinocytes have reported that Palmitoyl Tetrapeptide-7 reduces nuclear translocation of NF-κB subunits following pro-inflammatory stimulation, downregulating transcription of cytokine genes including IL-6, IL-1β, TNF-α, and PGE2.

Reduction of IL-6 Secretion

Interleukin-6 (IL-6) is a pleiotropic cytokine elevated in photoaged and chronologically aged skin. IL-6 promotes matrix metalloproteinase-1 (MMP-1) expression in dermal fibroblasts, accelerating collagen degradation. Research suggests that Palmitoyl Tetrapeptide-7 application reduces UV-induced and AGE-induced IL-6 secretion in fibroblast cultures by approximately 40–60% at micromolar concentrations, which has been associated with downstream reductions in MMP activity and improved extracellular matrix integrity.

Anti-Glycation and AGE Pathway Modulation

Advanced glycation end-products accumulate in long-lived dermal proteins such as collagen and elastin, where they form cross-links that increase stiffness and reduce elasticity. AGEs also engage the receptor for AGEs (RAGE) on fibroblasts, triggering further NF-κB activation in a feed-forward inflammatory loop. Palmitoyl Tetrapeptide-7 has been studied for its ability to interrupt this RAGE–NF-κB axis, indirectly limiting glycation-related inflammation rather than chelating AGE precursors directly.

Synergy with Matrixyl Peptides

Palmitoyl Tetrapeptide-7 is most often formulated alongside Palmitoyl Pentapeptide-4 (Matrixyl, KTTKS) or Palmitoyl Tripeptide-1 (GHK) in the Matrixyl 3000 and similar complexes. While Matrixyl peptides act as matrikines stimulating collagen, fibronectin, and glycosaminoglycan synthesis, Palmitoyl Tetrapeptide-7 reduces the inflammatory background that would otherwise degrade newly synthesised matrix. This complementary mechanism is the rationale for combination formulations used in topical anti-aging research.

Cellular Uptake

The palmitoyl chain anchors the peptide into cell membranes, where slow release of the GQPR fragment is thought to provide sustained intracellular signalling. Unlike receptor-binding peptides such as GHK-Cu, Palmitoyl Tetrapeptide-7 does not have a well-characterised single receptor; its activity appears to be mediated through intracellular modulation of inflammatory transcription factors rather than surface receptor engagement.

Palmitoyl Tetrapeptide-7 supplied by AminoCore Research for laboratory study is typically provided either as the single lipopeptide or as part of a complex (e.g., Matrixyl 3000-style blend). The table below documents the principal component, its base tetrapeptide sequence, and the related ingredients commonly co-formulated for synergy research.

Physical Characteristics

• Appearance: White to off-white lyophilised powder (neat peptide) or clear viscous solution (formulated complex)
• Solubility: Sparingly soluble in water due to palmitoyl chain; soluble in propylene glycol, glycerin, ethanol/water mixtures, and warm buffered solutions with mild surfactant
• Purity (neat peptide): ≥98% by HPLC
• Recommended use concentration: 1–10 ppm of active peptide in topical research formulations
• pH stability range: 4.5–7.0

Notes on Multi-Component Status

Because Palmitoyl Tetrapeptide-7 is most commonly studied as part of proprietary topical complexes, a single molecular formula and CAS for the finished blend are not meaningful. Researchers should reference the individual component CAS numbers above when documenting experimental protocols, and request a Certificate of Analysis specifying the active peptide content of the supplied material.

Palmitoyl Tetrapeptide-7 is supplied as a lyophilized powder or, in some preparations, as a pre-dissolved component of a multi-ingredient cosmetic research complex (e.g., Rigin™-style blends combining the peptide with glycerin and a preservative system). Because the molecule is a lipidated tetrapeptide (palmitic acid conjugated to the N-terminus of Gly-Gln-Pro-Arg), it exhibits amphiphilic behavior and requires careful solvent selection during reconstitution.

Recommended Reconstitution Protocol

1. Allow the vial to equilibrate to room temperature for 20–30 minutes after removal from -20°C storage. This prevents condensation forming on the lyophilized cake when the seal is broken.
2. Inspect the cake visually. A uniform white-to-off-white powder is expected. Any discoloration warrants discarding the vial.
3. Pre-dissolve in a small volume of warm (40–50°C) propylene glycol or 1,3-butylene glycol — typically 100–200 µL per mg of peptide. The palmitoyl chain reduces aqueous solubility, so a glycol co-solvent is required for clean dissolution.
4. Slowly add aqueous buffer or cosmetic vehicle with gentle swirling to bring the final concentration to the target working stock (typically 1,000–5,000 ppm in research formulations).
5. Do not vortex aggressively. Vigorous agitation can introduce air, denature the peptide, and cause foaming due to the amphiphilic structure. Use end-over-end rotation or gentle inversion.
6. Filter sterilise through a 0.22 µm PVDF (not PES) membrane if downstream use requires sterility. Avoid cellulose acetate filters, which can adsorb lipopeptides.

Working Concentration Guidance

Published in vitro cytokine studies have used Palmitoyl Tetrapeptide-7 at 5–50 ppm (5–50 µg/mL) in culture media. Topical research formulations typically incorporate the peptide complex at 1–3% w/w, which corresponds to approximately 30–100 ppm of the active peptide depending on the specific blend.

Compound-Specific Handling Notes

The arginine residue at the C-terminus is susceptible to oxidative degradation at elevated pH and temperature; maintain formulations between pH 5.0 and 6.5. The palmitoyl moiety is sensitive to lipase activity, so avoid contact with microbially contaminated water — always use freshly autoclaved or commercially sterile water for the aqueous phase. Wear nitrile gloves and work in a clean environment to prevent introduction of skin lipases.

Reconstituted material should be aliquoted into amber, low-binding polypropylene tubes to minimise photodegradation and surface adsorption losses.

Proper storage of Palmitoyl Tetrapeptide-7 is critical for maintaining the structural integrity of both the tetrapeptide backbone (Gly-Gln-Pro-Arg) and the conjugated palmitoyl chain. The lipidated nature of the molecule introduces stability considerations distinct from those of unmodified short peptides.

Lyophilized Powder Storage

• Long-term storage: -20°C in a frost-free freezer, protected from light, in the original sealed vial with desiccant. Under these conditions, the peptide remains stable for at least 24 months with no detectable HPLC purity loss in stability panels.
• Short-term storage: 2–8°C is acceptable for up to 30 days if the vial is unopened and protected from humidity.
• Transit: Ambient temperature exposure of up to 7 days during shipping has been shown not to compromise integrity for properly lyophilized material, although prolonged exposure above 30°C should be avoided.

Reconstituted Solution Storage

• 2–8°C (refrigerated): Reconstituted peptide in glycol/aqueous vehicle is typically stable for 2–4 weeks when stored in sterile, amber, low-binding containers with a compatible preservative system.
• -20°C: Aliquots may be frozen for up to 3 months, but avoid repeated freeze-thaw cycles. Each freeze-thaw cycle can introduce up to 2–5% purity loss due to peptide aggregation at the lipid-water interface.
• Room temperature: Not recommended for storage beyond active experimental use within a single working day.

Compound-Specific Stability Considerations

Arginine oxidation: The C-terminal arginine residue is susceptible to oxidative modification at elevated pH. Maintain reconstituted solutions between pH 5.0 and 6.5 to minimise this risk.

Palmitoyl hydrolysis: The amide bond linking the palmitic acid to the glycine N-terminus is generally stable but can undergo slow hydrolysis at extreme pH (<3 or >9) or in the presence of esterases/lipases. Avoid biological contamination.

Glutamine cyclization: The internal glutamine residue can undergo slow cyclization to pyroglutamate under prolonged storage at elevated temperatures, particularly above 25°C. This is detectable by HPLC as a slight retention shift.

Light sensitivity: Although the peptide lacks aromatic chromophores, prolonged UV exposure can accelerate oxidative pathways. Store in amber glass or opaque containers.